Satumba 8, 2025, InnoCare Pharma ta sanar da cewa Hukumar Kimiyyar Lafiya (HSA) ta Singapore ta amince da HIBRUKA (orelabrutinib) don maganin manya da ke fama da cutar lymphoma mai sake dawowa ko kuma mai jure wa yanayin zafi (R/R MZL).
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lymphoma na yankin Marginal (MZL) wani nau'in lymphoma ne na B-cell wanda ba Hodgkin's lymphoma ba (NHL) wanda galibi ke shafar marasa lafiya masu matsakaicin shekaru da tsofaffi. Yawan kamuwa da cutar MZL a duk duniya yana ƙaruwa a kowace shekara. Bayan maganin farko, marasa lafiya da ke fama da R/R MZL ba su da hanyoyin magani masu inganci.
A watan Afrilun 2025, orelabrutinib ya sami amincewa a China don maganin farko ga marasa lafiya da ke fama da cutar sankarar jini ta lymphocytic leukemia (CLL) / ƙananan lymphoma na lymphocytic (SLL). An kuma amince da Orelabrutinib don magance wasu alamu guda uku a China, ciki har da CLL/SLL da ke sake dawowa da kuma sake jurewa (R/R), r/r mantle cell lymphoma (R/R MCL) da r/r marginal zone lymphoma (R/R MZL), waɗanda duk an rufe su a cikin Jerin Magungunan Biyan Kuɗi na Ƙasa na China.
Inganci, Tsaro, da Hankali na Orelabrutinib Plus Obinutuzumab a cikin Jiyya Mai Tsari-Lymphoma na Yankin Marasa Lafiya: Wani Bincike Mai Zuwa na Ƙungiyar Masu Zaman Kansu ya nuna cewa a duk faɗin binciken da kuma yayin da ake yin maganin induction, jimillar amsawar (ORR) shine 100%. Marasa lafiya uku da ke da ɓangaren amsawar (PR) bayan an yi maganin induction sun sami cikakken amsawa (CR) yayin kulawa.
Gwaje-gwajen ADCC sun nuna cewa orelabrutinib tare da tsarin obinutuzumab ya haifar da mafi yawan amsawar ADCC a cikin layukan ƙwayoyin TMD-8 da REC-1.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lokacin Saƙo: Satumba-09-2025